8-K
filed December 19, 2022, 6:59 PM ET
ticker ORKA
CIK 0000907654
leadership
confidence high
sentiment neutral
materiality 0.60
ARCA biopharma elects James Flynn to Board; annual meeting results
Oruka Therapeutics, Inc.
- James Flynn elected to Board for term ending 2025 under cooperation agreement with Cable Car Capital.
- Flynn granted option to purchase 12,000 shares at $2.32; other directors each granted 6,000-share options.
- Stockholders elected Grais, Hove, Flynn; ratified KPMG as auditor; approved executive compensation.
- Board is evaluating strategic options for the company, per press release.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
James Flynn was elected as director at Oruka Therapeutics, Inc..
- Action
- elected
- Role
- director
Exact text from the filing
On December 15, 2022, the Board of Directors (the “Board”) of ARCA biopharma, Inc. (the “Company”) elected James Flynn, as a director of the Company.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2022-12-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-12-15
Exact text from the filing
1. Election of Directors: Nominee For Withheld Broker Non-Votes Dr. Linda Grais 5,625,386 192,401 3,296,871 Dr. Anders Hove 5,331,324 486,463 3,296,871 Mr. James Flynn 5,616,593 201,194 3,296,871
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-12-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2022-12-15
Exact text from the filing
2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For Against Abstentions Broker Non-Votes 8,980,366 116,906 17,386 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Oruka Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2022-12-15 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2022-12-15
Exact text from the filing
3. Executive Compensation: For Against Abstentions Broker Non-Votes 5,301,245 456,787 59,755 3,296,871
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.